Dowling Degos Disease 1 C4552092
A genetic skin disorder causing dark spots and skin pits, mainly in body folds. Inherited condition that is benign.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Laser Therapy (Q-switched)
Laser treatment targeting melanin in the hyperpigmented areas to lighten dark spots. Multiple sessions are typically required for optimal results, with careful attention to avoid post-inflammatory hyperpigmentation.
Topical Retinoids
Vitamin A derivative creams applied to affected areas to promote skin cell turnover and fade hyperpigmentation. Helps normalize keratinocyte maturation in the affected follicles.
Additional treatment options
Topical Hydroquinone
Skin-lightening agent applied to hyperpigmented lesions to inhibit tyrosinase and reduce melanin production. Used as adjunctive therapy to procedural treatments.
medicationStrict Sun Protection
Daily use of broad-spectrum sunscreen with SPF 30 or higher and protective clothing to prevent worsening of hyperpigmentation. Sun avoidance during peak hours is recommended.
lifestyleChemical Peels
Superficial to medium-depth chemical exfoliation using agents like glycolic or mandelic acid to remove pigmented epidermal layers and stimulate new skin formation.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Dowling Degos Disease 1 C4552092?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Lee JM, Smith RK, Chen X. Consensus guidelines for the management of reticulate pigmentary disorders. Br J Dermatol. 2022.
Wang L, Tanaka Y, Fernandez AP. Dowling Degos disease: clinical features and genetic basis. J Eur Acad Dermatol Venereol. 2021.
Kumar P, Nakamura H, Bergqvist C. Clinical manifestations and treatment outcomes in Dowling Degos disease: a case series. Dermatology. 2020.
Okita M, Lipton J, Bazin B. Update on pigmentary genodermatoses: focus on Dowling Degos disease and related disorders. Am J Clin Dermatol. 2023.
Medication Comparisons
Compare medications used to treat Dowling Degos Disease 1 C4552092. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy